7 results on '"Kramp, Birgit K."'
Search Results
2. Controlled intramyocardial release of engineered chemokines by biodegradable hydrogels as a treatment approach of myocardial infarction
- Author
-
Projahn, Delia, Simsekyilmaz, Sakine, Singh, Smriti, Kanzler, Isabella, Kramp, Birgit K., Langer, Marcella, Burlacu, Alexandrina, Bernhagen, Jürgen, Klee, Doris, Zernecke, Alma, Hackeng, Tilman M., Groll, Jürgen, Weber, Christian, Liehn, Elisa A., and Koenen, Rory R.
- Published
- 2014
- Full Text
- View/download PDF
3. Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice
- Author
-
Koenen, Rory R., von Hundelshausen, Philipp, Nesmelova, Irina V., Zernecke, Alma, Liehn, Elisa A., Sarabi, Alisina, Kramp, Birgit K., Piccinini, Anna M., Paludan, Soren R., Kowalska, M. Anna, Kungl, Andreas J., Hackeng, Tilman M., Mayo, Kevin H., and Weber, Christian
- Subjects
Atherosclerosis -- Risk factors ,Atherosclerosis -- Prevention ,Atherosclerosis -- Research ,Blood platelets -- Physiological aspects ,Chemokines -- Physiological aspects ,Chemokines -- Research - Abstract
Atherosclerosis is characterized by chronic inflammation of the arterial wall due to chemokine-driven mononuclear cell recruitment (1-4). Activated platelets can synergize with chemokines to exacerbate atherogenesis; for example, by deposition of the chemokines platelet factor-4 (PF4, also known as CXCL4) and RANTES (CCL5), triggering monocyte arrest on inflamed endothelium (5-9). Homo-oligomerization is required for the recruitment functions of CCL5, and chemokine heteromerization has more recently emerged as an additional regulatory mechanism, as evidenced by a mutual modulation of CXCL8 and CXCL4 activities and by enhanced monocyte arrest resulting from CCL5-CXCL4 interactions (10-13). The CCL5 antagonist Met-RANTES reduces diet-induced atherosclerosis (9,14); however, CCL5 antagonism may not be therapeutically feasible, as suggested by studies using Ccl5-deficient mice which imply that direct CCL5 blockade would severely compromise systemic immune responses, delay macrophage-mediated viral clearance and impair normal T cell functions (15,16). Here we determined structural features of CCL5-CXCL4 heteromers and designed stable peptide inhibitors that specifically disrupt proinflammatory CCL5-CXCL4 interactions, thereby attenuating monocyte recruitment and reducing atherosclerosis without the aforementioned side effects. These results establish the in vivo relevance of chemokine heteromers and show the potential of targeting heteromer formation to achieve therapeutic effects., To unequivocally establish the involvement of blood cell-derived and largely platelet-secreted Ccl5 and Cxcl4 in diet-induced atherosclerosis, we repopulated apolipoprotein E (Apoe)-deficient mice with [Ccl5.sup.-/-] , [Pf4.sup.-/-] or wild-type bone [...]
- Published
- 2009
4. Establishing the interaction between the CC chemokine ligand 5 and the receptors CCR1 and CCR5
- Author
-
Kramp, Birgit K. and Koenen, Robert Ryan
- Subjects
Wechselwirkung ,CCL5 ,%22">Ligand ,virus diseases ,Interaktion ,CCR5-Rezeptor ,später ,stomatognathic diseases ,RANTES ,stomatognathic system ,Biowissenschaften, Biologie ,Chemokine ,ddc:570 ,CCR1 ,Chemokininteraktion - Abstract
Chemokines are important mediators and regulators of leukocyte trafficking, therefore, they play a crucial role in the development of inflammatory diseases. CCL5 or RANTES (regulated upon activation, normal T cell expressed and secreted) is a chemokine of relevance to many diseases. Moreover, CCL5-induced monocyte adhesion to inflamed endothelium was shown to be improved in the presence of CXCL4 (Platelet Factor 4). Since this synergy could be attributed to heterodimer formation, the first section of the present study surveys the structural interaction of CCL5 with CXCL4. The interaction was monitored employing the 15N-1H heteronuclear single quantum coherence (HSQC) nuclear magnetic resonance (NMR) technique. For this purpose, 15N-enriched CCL5 was recombinantly expressed in E. coli and subsequently purified. In HSQC spectroscopy, chemical shift changes were mainly observed in the N-terminal residues, which pointed toward a CC-type rather than a CXC-type interaction. Furthermore, small peptide antagonists, inhibiting the CXCL4/CCL5 dimerization, were designed (CKEY2 and the mouse orthologue MKEY). To investigate their pharmacological potential, the influence of MKEY on leukocyte adhesion to activated endothelium was monitored using intravital microscopy. As a control Met-CCT5, a strong antagonist for CCR1 and CCR5, was cloned, expressed and purified employing FPLC and HPLC techniques. Leukocyte recruitment was severely impaired in the presence of MKEY, compared to a control peptide (sMKEY) and in a similar range of Met-CCL5 which encourages the assumption that the synergy is mediated via the receptors CCR1 and/or CCR5. Despite all similarities, CCR1 and CCR5 were shown to mediate distinct functions when bound to CCL5, CCR1 rather mediates arrest and CCR5 appears to be more responsible for transendothelial migration. To establish which domains are important for this functional selectivity, we constructed different CCR5 variants with the distinct extracellular regions of CCR1. These chimeras were stably expressed in L1.2 and HEK293 cells and we investigated their function in response to CCL5, different CCL5 mutants, or together with CXCL4 using chemotaxis and cell arrest assays under laminar flow. First of all, CCL5, CCL5 40s and CCL5-E66A were recombinantly expressed and purified employing FPLC and HPLC techniques. By implementing CCL5 mutants (e.g. CCL5-E66A) with oligomerization defects in laminar flow assays, we were able to show that all receptor variants require oligomerization of CCL5 in order to function properly. In addition, our results reveal that the 40S loop of CCL5 is important for both the CCR1- and CCR5-mediated cell arrest. The 50s loop of CCL5, however, appeared to have a strong preference for CCR5 in inducing cell arrest, since CCR1 responded normal towards CCL5 50s and CCR5 being non-responsive. When the N-terminal domain of CCR5 was exchanged for that of CCR1, the resulting chimera was fully responsive towards CCL5 50s, suggesting that the N-terminal region of CCR1 interacts with the 50s domain of CCR5. The synergistic effect of CXCL4 on CCL5 induced cell arrest was observed in cells exclusively expressing CCR1 when compared to cells expressing CCR5. When the third extracellular loop of CCR1 was engineered into CCR5, the resulting chimeric receptor showed a significant response to the CXCL4/CCL5 heterocomplex, compared to CCL5 alone. These results were confirmed by constructing CCR1-based reverse chimeras for the N-terminal domain and the third extracellular loop. Furthermore we could show the heterodimerization of CCR1 and CCR5 and the synergy of the CXCL4/CCL5 complex is in THP-1 cells mediated via Gαi. In conclusion these results indicate that the extracellular regions of CCR1 and CCR5 have distinct and defined functions in leukocyte recruitment in response to CCL5. In the third section of this thesis the role of the sialyltransferase ST3Gal-IV on CCL5 receptor interaction was investigated, by using neutrophils and monocytes isolated from ST3Gal-IV deficient and from control mice in functional assays in vitro. The results indicate that the addition of sialic acids to the terminal portions of the N- or O-linked sugar chains of the corresponding receptors of CCL5 is of a minor importance for receptor binding and activation, since the cells similarly mobilize calcium upon stimulation with CCL5. Whereas, the adhesion of neutrophils and monocytes from ST3Gal-IV-/- was significant diminished. Taken together the results obtained here rather support the importance of ST3Gal-IV on the generation of functional selectins, which is in line with previous publications.
- Published
- 2013
5. Exchange of extracellular domains of CCR1 and CCR5 reveals confined functions in CCL5-mediated cell recruitment
- Author
-
Kramp, Birgit K., primary, Megens, Remco T. A., primary, Sarabi, Alisina, primary, Winkler, Sabine, primary, Projahn, Delia, primary, Weber, Christian, primary, Koenen, Rory R., additional, and von Hundelshausen, Philipp, additional
- Published
- 2013
- Full Text
- View/download PDF
6. Contribution of Platelet CX 3 CR1 to Platelet–Monocyte Complex Formation and Vascular Recruitment During Hyperlipidemia
- Author
-
Postea, Otilia, primary, Vasina, Elena M., additional, Cauwenberghs, Sandra, additional, Projahn, Delia, additional, Liehn, Elisa A., additional, Lievens, Dirk, additional, Theelen, Wendy, additional, Kramp, Birgit K., additional, Butoi, Elena D., additional, Soehnlein, Oliver, additional, Heemskerk, Johan W.M., additional, Ludwig, Andreas, additional, Weber, Christian, additional, and Koenen, Rory R., additional
- Published
- 2012
- Full Text
- View/download PDF
7. Contribution of platelet CX(3)CR1 to platelet-monocyte complex formation and vascular recruitment during hyperlipidemia.
- Author
-
Postea O, Vasina EM, Cauwenberghs S, Projahn D, Liehn EA, Lievens D, Theelen W, Kramp BK, Butoi ED, Soehnlein O, Heemskerk JW, Ludwig A, Weber C, and Koenen RR
- Subjects
- Animals, Atherosclerosis genetics, Atherosclerosis metabolism, Atherosclerosis pathology, Blotting, Western, CX3C Chemokine Receptor 1, Cell Line, Disease Models, Animal, Endothelium, Vascular pathology, Flow Cytometry, HIV-2, Humans, Hyperlipidemias metabolism, Hyperlipidemias pathology, Immunohistochemistry, Mice, Mice, Inbred C57BL, Platelet Activation, Real-Time Polymerase Chain Reaction, Receptors, Cytokine biosynthesis, Receptors, HIV biosynthesis, Blood Platelets metabolism, Endothelium, Vascular metabolism, Gene Expression Regulation, Hyperlipidemias genetics, Monocytes metabolism, RNA, Messenger genetics, Receptors, Cytokine genetics, Receptors, HIV genetics
- Abstract
Objective: The chemokine receptor CX(3)CR1 is an inflammatory mediator in vascular diseases. On platelets, its ligation with fractalkine (CX(3)CL1) induces platelet activation followed by leukocyte recruitment to activated endothelium. Here, we evaluated the expression and role of platelet-CX(3)CR1 during hyperlipidemia and vascular injury., Methods and Results: The existence of CX(3)CR1 on platelets at mRNA and protein level was analyzed by RT-PCR, quantitative (q)PCR, FACS analysis, and Western blot. Elevated CX(3)CR1 expression was detected on human platelets after activation and, along with increased binding of CX(3)CL1, platelet CX(3)CR1 was also involved in the formation of platelet-monocyte complexes. Interestingly, the expression of CX(3)CR1 was elevated on platelets from hyperlipidemic mice. Accordingly, CX(3)CL1-binding and the number of circulating platelet-monocyte complexes were increased. In addition, CX(3)CR1 supported monocyte arrest on inflamed smooth muscle cells in vitro, whereas CX(3)CR1-deficient platelets showed decreased adhesion to the denuded vessel wall in vivo., Conclusions: Platelets in hyperlipidemic mice display increased CX(3)CR1-expression and assemble with circulating monocytes. The formation of platelet-monocyte complexes and the detection of platelet-bound CX(3)CL1 on inflamed smooth muscle cells suggest a significant involvement of the CX(3)CL1-CX(3)CR1 axis in platelet accumulation and monocyte recruitment at sites of arterial injury in atherosclerosis.
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.